Stock Fundamentals

Aurobindo Pharma: Good medium to grow

Dhuraivel Gunasekaran | Updated on November 25, 2018 Published on November 25, 2018

Healthy growth prospects and the company’s acquisitions should pay off over time

Despite a reasonably healthy show in the September quarter, the stock of Aurobindo Pharma’s fell significantly. It is, however, up 19 per cent from our previous recommendation in November 2017.

The company’s growth prospects look robust in the medium to long run. The stock is still attractive from a valuation perspective, and trades at a significant discount to peers. At the current price of ₹803, the stock trades at about 15 times its likely per share earnings for 2019-20, compared to 20-plus times that peers such as Lupin, Sun Pharma, Cipla and Dr Reddy’s enjoy.

Aurobindo is attractively placed to deliver sustainable growth over the next two to three years, given the multiple growth drivers in its US and European operations, improving profit visibility in growth markets and its antiretroviral business. Investors with a long-term horizon can consider buying the stock at current levels.

Growing US presence

Over the years, Aurobindo has been taking the inorganic route to expand and enhance its product portfolio offerings in key therapeutic areas across the globe. Recently, the company entered into an agreement with US-based Sandoz to acquire its US dermatology and oral solid businesses for $900 million. This deal is likely to add approximately 300 products to Aurobindo’s portfolio.

The acquisition is expected to be closed in CY19. After that, the company will become the second largest generic player (based on prescriptions) and the second largest dermatology player in the US. The generic derma business has been a strong profit driver in the US. The management expects the acquisition will bring annual net sales of $900 million. Though there will be significant debt addition due to the recent deals, the company is well-placed to manage this by consistent and incremental cash flows. At present, the company has a comfortable net debt-to-equity ratio of 0.4, as on FY18.

Currently, the company’s US business accounts for 47 per cent of the total revenue. While many major pharma players are struggling to do business in the US, Aurobindo has been gaining volumes in US, thanks to its low product concentration and strong pipeline across therapeutic areas.

The management is confident of strong volume growth in its existing portfolio, new launches and ramp-up of injectables in its US business. While there is immense pricing pressure seen in the oral solids space, the company is well-positioned to grow its revenue, going ahead, with a total 510 ANDA filings (as of September 2018). The management expects US filings to remain healthy at 40-50 per annum over the next five years.

Among Indian players, Aurobindo has the largest number of products in its injectables portfolio, which are expected to be strong growth drivers in the US going ahead. The management has guided for 30 per cent growth in injectables for FY19 on the back of continuous traction from ertapenem injection (anti-infective), besides a few other launches.

In the medium-term road map (from 2019-2021), Aurobindo has indicated that it will focus on launching oncology, respiratory, complex injectables and topical products in the US.

Traction in Europe business

The company’s Europe business (contributes 26 per cent of total revenue) has gained traction significantly over the last few years, driven by tenders, especially from large markets such as the UK, France and Germany. The management has guided for 8-10 per cent growth in Europe over the next few years.

Recently, the company also acquired Canada-based Apotex businesses in five European countries (Poland, Czech Republic, the Netherlands, Spain, and Belgium) for around €74 million. This acquisition will add 200 generics and more than 80 OTC products that had total sales of €133 million in FY18. The acquisition is expected to be completed by FY19-end, which would lead to further growth in the EU.

The company has transferred 97 products pertaining to Europe to India. Profitability in the European business should continue to improve, as shifting the products to India should aid margins in the medium to long term.

Ramp up in ARV business

The antiretroviral (ARV) business (drugs treating HIV) of the company is gaining traction, barring dolutegravir (DTG) triple combination drug, which is facing issues due to certain side-effects. Currently, the ARV business contributes around 5 per cent to the total revenue.

Aurobindo has maintained its guidance for R&D spends at 5 per cent of sales in FY19.

Financials

In the first half of 2018-19, Aurobindo’s consolidated net sales was ₹8,849 crore, up 11 per cent over the same period last year.

Consolidated net profit was ₹1,067 crore, down by 18 per cent Y-o-Y.

Published on November 25, 2018

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor